Mogg Karin, Bradley Brendan P, O'Neill Barry, Bani Massimo, Merlo-Pich Emilio, Koch Annelize, Bullmore Edward T, Nathan Pradeep J
Department of Psychology, University of Southampton, Southampton, UK.
Behav Pharmacol. 2012 Sep;23(5-6):603-8. doi: 10.1097/FBP.0b013e3283566a4a.
The aim of the study was to examine the effect of manipulating the brain dopamine system, using a D₃ receptor antagonist, on approach responses to food cues in overweight and obese individuals. Twenty-six healthy overweight and obese participants were randomly assigned to receive either a single dose of dopamine D₃ receptor antagonist, GSK598809 (175 mg), or placebo in the first assessment session and vice versa in the second session. Using a stimulus-response compatibility task, approach bias was indexed by response latency to move an image of a manikin towards, versus away from, pictures of food, relative to nonfood stimuli. Data from the first session (which were unaffected by repeated testing) indicated that approach bias scores were significantly reduced in overweight and obese participants who received GSK598809, compared with those who received placebo. Data from the second session were confounded by an effect of treatment order and, consequently, were uninformative for the hypotheses. Between-participant comparison of drug versus placebo conditions indicated that GSK598809 attenuated approach bias to food cues, which is consistent with the reduction in their motivational attractiveness. The findings, albeit preliminary, are in agreement with the view that D₃ receptor antagonists may prove useful as therapeutic agents for reducing appetitive responses to food cues in obesity.
本研究的目的是使用D₃受体拮抗剂来操纵大脑多巴胺系统，以考察其对超重和肥胖个体对食物线索的趋近反应的影响。26名健康的超重和肥胖参与者在第一次评估 session 中被随机分配接受单剂量多巴胺D₃受体拮抗剂GSK598809（175毫克）或安慰剂，在第二次session中则相反。使用刺激-反应兼容性任务，通过相对于非食物刺激，将人体模型图像移向或远离食物图片的反应潜伏期来衡量趋近偏向。第一次session的数据（不受重复测试影响）表明，与接受安慰剂的参与者相比，接受GSK598809的超重和肥胖参与者的趋近偏向得分显著降低。第二次session的数据因治疗顺序的影响而混淆，因此对假设无信息价值。药物与安慰剂条件的参与者间比较表明，GSK598809减弱了对食物线索的趋近偏向，这与它们动机吸引力的降低一致。这些发现尽管是初步的，但与D₃受体拮抗剂可能被证明是减少肥胖个体对食物线索的食欲反应的治疗药物这一观点一致。
